PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO
Abstract
Authors
A Juarez-Garcia L Zapata G Vega J Idrovo R Rivas JL Kramis G Litalien S Rangel